Protagonist (Nasdaq: PTGX) is one of a handful of Bay Area drug developers ready to ask the Food and Drug Administration to ...

Takeda boosts profit margins with AI-driven growth, FY2024 guidance upgrade, share buyback plan & promising drug launches.

Explore Modern Aminos' breakthrough in Aminos Research. Discover benefits of Retatrutide Peptide & gain actionable insights for advanced laboratory studies ...

Learn more about whether Alvotech or Protagonist Therapeutics, Inc. is a better investment based on AAII's A+ Investor grades ...

Results from the company’s Phase II trial also saw PL8177 elicit a clinical response in 77% of ulcerative colitis patients.